C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics

Summary

In a residency clinic in Baltimore, the investigators propose to conduct a pilot RCT comparing a) an avatar-delivered computerized intervention (CI) for tobacco cessation augmented with CHW support and navigation to lung cancer screening to b) a waitlist control.

With a sample of participants from the residency clinic (N=30), the investigators will collect data on feasibility of recruitment, intervention engagement and completion, and short-term smoking cessation outcomes. Individuals will be assessed at baseline, 1 month, 3 months, and 6 months. The investigators will conduct interviews with a subset of pilot participants to collect qualitative data on intervention acceptability.

Conditions

• Tobacco Dependence

Interventions

BEHAVIORAL

C-Raven Virtual Tobacco Cessation Counseling

A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.

DRUG

Nicotine Replacement Product

Participants will be offered up to a 12-week supply of nicotine patches and either nicotine gum or lozenges.

OTHER

Community Health Worker

A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.

OTHER

Lung Cancer Screening

After participating in shared decision-making, eligible participants will be referred to primary care physician or existing specialist to complete lung cancer screening.

Sponsors & Collaborators

• Maryland Cigarette Restitution Fund

  collaborator OTHER_GOV

• Johns Hopkins University

  lead OTHER

Principal Investigators

• Alejandra Ellison-Barnes, MD · Johns Hopkins School of Medicine

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-10

Primary Completion

2026-06-30

Completion

2027-06-30

FDA Drug

Yes

Countries

• United States

Study Locations